Prospects for restorative therapy in patients after antitumor treatment for cervical and uterine cancer
Pokul L.V., Bebneva T.N., Novginov D.S.
Objective: Evaluation of the effectiveness of combination therapy for epitheliitis in patients after antitumor treatment for cervical and uterine cancer. Tyndallized lactobacilli and lactoferrin (DuoLact®) in combination with organic olive oil enriched with vitamin E (EvoGold®) – part of DermOlivo® Pentcroft® products - were used.
Materials and methods: The study included 113 women aged 30 to 70 years with cervical cancer (T1aN0M0-T3N0M0, T1bN1M0-T3N1M0), and uterine cancer (T1bN0M0-T2N0M0). The patients were divided into two groups. Group I (n=53) received DermOlivo® Pentcroft® (suppositories and oil) in combination with methyluracil ointment. Group II (n=60) received methyluracil ointment alone. Therapy lasted 3 weeks daily, then 3 times a week for 3 months (15 weeks).
Results: After the first three weeks of continuous treatment, vaginal tension persisted in 20.8% (11/53) of patients in Group I, while in 61.7% (37/60) in Group II. Painless intercourse was observed in 77% (41/53) of women in Group I, compared to only 47% (28/60) in Group II.
Relief of dyspareunia symptoms after 15 weeks was observed in 92.5% (49/53) of cases in Group I, compared to only 41.7% (25/60) in Group II. Complete healing of erosions was observed in 90.6% (48/53) of patients in Group I. Three months after the end of treatment (a full 15-week cycle), vaginal dryness and occasional hemorrhages persisted in only 13.2% (7/53) of cases in Group I; in Group II, pathological changes in the vaginal mucosa were recorded in 33.3% (20/60) of cases. After both 3 weeks and 3 months, a statistically significant decrease in the pH index was observed in Group I compared to Group II. After 3 weeks, the incidence of severe vulvovaginal atrophy (VVA), assessed as 5 points on the D. Barlow scale, decreased by 3.4 times in Group I, while in Group II it decreased only by 1.6 times. At the same time, the incidence of 1 point in Group I increased by 7 times, while in Group II it only increased by 1.5 times. Three months after the end of treatment, Group I did not have any patients with severe VVA manifestations (4 and 5 points); the proportion of respondents with mild disorders (1 point) increased to 79.2% (42/53). Meanwhile, in Group II, only 18.3% (11/60) of observations had 1 point on the D. Barlow scale; There were also no patients with severe VVA (rated at 5 points), but there were patients with a VVA score of 4. Immune status indicators (ISI) returned to normal in Group I after just 3 weeks.
Conclusion: DermOlivo® Pentcroft® suppositories and oil, in combination with standard drug therapy, demonstrated high efficacy and safety in the prevention and treatment of early radiation complications (epitheliitis), including VVA, in patients after antitumor treatment for cervical and uterine cancer.
For citations: Pokul L.V., Bebneva T.N., Novginov D.S. Prospects for restorative therapy in patients after antitumor treatment for cervical and uterine cancer. Pharmateca. 2026;33(1):112-122. (In Russ.). DOI: https://dx.doi.org/10.18565/pharmateca.2026.1.112-122
Authors’ contribution: L.V. Pokul and T.N. Bebneva – study planning, design, and data collection. D.S. Novginov – text editing, article translation, and section writing.
Conflicts of interest: The authors confirm that they have no conflicts of interest to declare.
Funding: The study was conducted without any sponsorship.
Ethical Approval: The study was approved by Ekaterinodar LLC.
Patient Consent for Publication: All patients provided informed consent for the publication of their data.
Authors’ Data Sharing Statement: The data supporting the findings of this study are available upon request from the corresponding author after approval from the principal investigator.
Keywords
cervical and uterine cancer after antitumor treatment
early radiation damage
epitheliitis
vulvovaginal atrophy
DermOlivo® Pentcroft® oil and vaginal suppositories
About the Authors
Liliana V. Pokul, Dr. Sci. (Med.), Professor, Department of Obstetrics and Gynecology with a Course in Perinatology, Peoples’ Friendship University of Russia named after Patrice Lumumba (Moscow); Oncologist, Obstetrician-Gynecologist, Ekaterinodar LLC, Goryachy Klyuch, Russia; ORCID: https://orcid.org/0000-0002-3877-4883 (corresponding author)Tamara N. Bebneva, Dr. Sci. (Med.), Associate Professor, Department of Obstetrics, Gynecology, and Reproductive Medicine, Faculty of Continuous Medical Education, Medical Institute, Peoples’ Friendship University of Russia named after Patrice Lumumba; Obstetrician-Gynecologist, I.I. Dedov National Medical Research Center of Endocrinology, Moscow, ORCID: https://orcid.org/0000-0003-1095-2008
Dmitry S. Novginov, Cand, Sci. (Med.), Associate Professor, Department of Obstetrics and Gynecology with a course of Perinatology, Peoples’ Friendship University of Russia named after Patrice Lumumba, Moscow, Russia; ORCID: https://orcid.org/0000-0002-7184-8469
Similar Articles
